Saturday, September 24, 2016 5:48:35 PM
A "stigmatizing blue dye" is a novel use of blue dye. That's why many are surprised there was no Safety & Efficacy Phase 3 requirement. The "general use" referred to in the docuent you cite is a concentration required to make a blue tablet. Rexista contains a concentration of blue dye sufficient to humiliate an abuser with blue lips, blue gums, and blue teeth. But to the normal user, this is twice daily concentrated doses of a possible carcinogen-- twice daily indefinitely-- without any benefit at all to the normal user. Again, even if prescribed by another practitioner, I would feel ethically-obligated to advise my patients to refuse to take it for this reason.
But the turning blue & pissing blue & shitting blue & bleeding blue & then croaking blue is a real damn thing. If the blue dye is going down the same hole, then it makes no difference if the dye came from a tablet or a tube feed. They are both going into the stomach and processing through the G.I. tract. And the tube feeds were short-term, but Rexista will deliver blue dye forever.
Look at the FDA advisory. The effect was independent of time & dose, but it was associated with sepsis from infections. Chronic pain is proven immunosuppressive, and studies suggest use of chronic opioids is immunosuppressive. For sure chronic pain patients are more likely to have medical comorbidities, such as diabetes and peripheral vascular disease, that increase their risk of infections. Someone taking 100mg+ of oxycodone every day is at higher risk for sepsis associated with skin infections, aspiration pneumonia, or opioid-induced ileus/bowel obstruction. Sepsis is a generalized whole-body inflammatory response to a focal infection, such as UTI or pneumonia. Once the sepsis syndrome begins, the G.I. tract permeability becomes altered, and the presence of the blue dye seems to hasten onset of severe sepsis and death from multi-system organ failure, despite full life-support measures.
Are you on gluten-free diet because of celiac sprue? Do you have kidney problems? Do you take pain medicine because of Crohn's or ulcerative colitis? Trauma? Surgery? The FDA Advisory specifically warns that you are at increased risk from the blue dye that will be in Rexista-- without any benefit to you at all. Hard to believe these guys are going to get away without doing a Safety & Efficacy Phase 3 Study. BWAHAHAHA if you like, but mark this post, the blue dye will cause problems for Rexista, maybe already has. I can't wait for the Rexista AdComm. I'm going to take that day off work.
Doesn't matter how the blue dye got there-- people with blue dye in their gut when they become septic can turn blue & die before they ever have a chance to seek help. Not my patients. Any responsible physician should refuse to prescribe this drug until safety is well-established.
http://www.fda.gov/ForIndustry/ColorAdditives/ColorAdditivesinSpecificProducts/InMedicalDevices/ucm142395.htm
Historic note: Until his life's destiny was further clarified, Robin Hood spent several years robbing from the rich and giving to the porcupines. (G. Larson 7/26/82)
Recent IPCI News
- Suspension de la négociation par l'Organisme canadien de réglementation des investissements - IPCI • PR Newswire (Canada) • 03/06/2024 12:55:00 PM
- Canadian Investment Regulatory Organization Trading Halt - IPCI • PR Newswire (Canada) • 03/06/2024 12:51:00 PM
- L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - IPCI • PR Newswire (Canada) • 06/08/2023 05:30:00 PM
- Canadian Investment Regulatory Organization Trade Resumption - IPCI • PR Newswire (Canada) • 06/08/2023 05:28:00 PM
- Intellipharmaceutics Announces Fiscal Year 2022 and First Quarter 2023 Results • PR Newswire (Canada) • 06/06/2023 10:00:00 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM